Virios Therapeutics’s Earnings Outlook

Virios Therapeutics (NASDAQ:VIRI) is set to give its latest quarterly earnings report on Thursday, 2023-08-10. Here’s what investors…

Virios Therapeutics (NASDAQ:VIRI) is set to give its latest quarterly earnings report on Thursday, 2023-08-10. Here’s what investors need to know before the announcement.

Analysts estimate that Virios Therapeutics will report an earnings per share (EPS) of $-0.07.

Virios Therapeutics bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.12, which was followed by a 0.0% drop in the share price the next day.

Here’s a look at Virios Therapeutics’s past performance and the resulting price change:

Quarter Q1 2023 Q4 2022 Q3 2022 Q2 2022
EPS Estimate -0.20 -0.15 -0.49 -0.51
EPS Actual -0.08 -0.11 -0.28 -0.44
Price Change % 0.0% -4.32% -3.79% 13.13%

eps graph

Stock Performance

Shares of Virios Therapeutics were trading at $1.69 as of August 08. Over the last 52-week period, shares are down 79.46%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

To track all earnings releases for Virios Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Luminar Technologies Stock Jumps On Earnings As Company Reveals Tesla Was Biggest Customer In Q1

Luminar reported first-quarter revenue of $20.97 million, which missed the consensus estimate of $21.14 million, per Benzinga Pro. The company's top-line results were up 45% on a year-over-year basis, but down 5% sequentially. Luminar reported a first-quarter adjusted earnings loss of 19 cents per share, which beat estimates for a loss of 20 cents per share.

LAZR